Immune cell treatment to control CMV or adenovirus after transplant
Part of Infections clinical trials.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a solid organ transplant or an allogeneic bone marrow transplant
- You are in the right group: either CMV (Cohort A) or adenovirus (Cohort B) with confirmed infection/reactivation or high-risk features
- Your virus problem should be current enough to require treatment (for example, a lab viral load above study cutoffs or new/worsening symptoms)
- You must have a donor available whose immune type matches you well enough for this study
- You must be stable enough for study procedures (not have uncontrolled, rapidly worsening infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.